|
Status |
Public on Dec 17, 2011 |
Title |
B6D2F1_WAP_T121_p53null_KS50_SIMIN |
Sample type |
RNA |
|
|
Channel 1 |
Source name |
Mouse reference
|
Organism |
Mus musculus |
Characteristics |
reference: Whole mouse total RNA
|
Biomaterial provider |
Cam Patterson-UNC-CH
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was purified from 20-30 mg tissue of end-stage tumors using the Qiagen RNeasy Mini Kit according to the manufacturer’s protoco.
|
Label |
Cy3
|
Label protocol |
Two micrograms of total RNA was reverse transcribed, amplified and labeled using the Low RNA Input Amplification kit (Agilent).
|
|
|
Channel 2 |
Source name |
B6D2F1_WAP_T121_p53null_KS50_SIMIN
|
Organism |
Mus musculus |
Characteristics |
test: mammary tumor
|
Biomaterial provider |
Karl Simin
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was purified from 20-30 mg tissue of end-stage tumors using the Qiagen RNeasy Mini Kit according to the manufacturer’s protoco.
|
Label |
Cy5
|
Label protocol |
Two micrograms of total RNA was reverse transcribed, amplified and labeled using the Low RNA Input Amplification kit (Agilent).
|
|
|
|
Hybridization protocol |
The amplified sample and reference were co-hybridized overnight to Agilent Mouse Oligo Microarrays (G4121A) according the manufacturer's protocol.
|
Scan protocol |
Fluorescent array images were collected for both Cy3 and Cy5 with a GenePix 4000B fluorescent scanner.
|
Description |
B6D2F1_WAP_T121_p53null_KS50_SIMIN
|
Data processing |
Image intensity data were extracted and analyzed with GenePix Pro 4.1 analysis software. Data for both channels were Lowess-normalized and then log(2) ratio was taken.
|
|
|
Submission date |
Dec 15, 2011 |
Last update date |
Dec 17, 2011 |
Contact name |
Karl Simin |
E-mail(s) |
karl.simin@umassmed.edu
|
Organization name |
UMass Medical School
|
Street address |
364 Plantation St.
|
City |
Worcester |
State/province |
MA |
ZIP/Postal code |
01606 |
Country |
USA |
|
|
Platform ID |
GPL891 |
Series (1) |
GSE34479 |
Cooperativity of Rb, Brca1, and p53 and malignant breast cancer evolution |
|